Compounds > benzimidazolone
Page last updated: 2024-12-07

benzimidazolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Benzimidazolone is a heterocyclic compound that serves as a core structure for a variety of biologically active molecules. It is often synthesized via condensation reactions involving o-phenylenediamine and a suitable carbonyl compound. Benzimidazolones exhibit a diverse range of pharmacological effects, including anti-inflammatory, antimicrobial, and anticancer activities. They are particularly important as building blocks for the development of novel therapeutic agents. The study of benzimidazolones is driven by their potential to address various health challenges, particularly in areas like infectious diseases and cancer. Their unique chemical structure and biological activity make them a promising area of research for the discovery of new drugs.'

Cross-References

ID SourceID
PubMed CID88638
CHEMBL ID3331429
SCHEMBL ID9876669
SCHEMBL ID44492
MeSH IDM0062832

Synonyms (79)

Synonym
AC-13177
1-(piperidin-4-yl)-1h-benzimidazol-2-ol
EN300-34383
4-(2-keto-1-benzimidazolinyl)piperidine, 98%
SR-01000630997-1
20662-53-7
1-(4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one
AKOS000268914
SCHEMBL9876669
3-piperidin-4-yl-1h-benzimidazol-2-one
4-(2-keto-1-benzimidozolinyl)piperidine
4-(2-keto-1-benzimidozolinyl) piperidine
4-(1-benzimidazolinone)piperidine
4-(2'-oxobenzimidazolin-1'-yl)piperidine
unii-4rp0aed2pc
einecs 243-950-3
4rp0aed2pc ,
STK519516
A814790
1-(piperidin-4-yl)-1,3-dihydro-2h-benzo[d]imidazol-2-one;1-(piperidin-4-yl)-1h-benzo[d]imidazol-2(3h)-one
1-(piperidin-4-yl)-1h-benzo[d]imidazol-2(3h)-one
1-(piperidin-4-yl)-2,3-dihydro-1h-1,3-benzodiazol-2-one
4-(2-keto-1-benzimidazolinyl)piperidine
CCG-40889
AKOS005177353
BP-12472
AM84716
1-(piperidin-4-yl)-1,3-dihydro-2h-benzimidazol-2-one
2h-benzimidazol-2-one, 1,3-dihydro-1-(4-piperidinyl)-
r-30507
4-(2-oxo-1-benzimidazolinyl)piperidine
1-(4-piperidinyl)-2-benzimidazolone
pimozide impurity a [ep impurity]
4-(2-oxo-1,3-dihydrobenzimidazol-1-yl)piperidine
4-(2-oxo-1,3-dihydro-2h-benzimidazol-1-yl)piperidine
4-(2-oxo-1-benzimidazoly)piperidine
4-(2-keto-1-benzimidazolinyl)-piperidine
4-(2-keto-1-benzoimidazolinyl)piperidine
4-(2-oxo-1-benzimidazolinyl) piperidine
1-(4-piperidinyl)-2-oxobenzimidazoline
1-(4-piperidyl)-2-benzimidazolinone
4-(2-keto-1 - benzimidazolinyl)piperidine
4-piperidyl-2-benzimidazolinone
1-(4-piperidinyl)-1,3-dihydro-2(2h)-benzimidazolone
1-(4-piperidinyl)-2-benzimidazolinone
4-(2-oxobenzimidazolin-1-yl)piperidine
BYNBAMHAURJNTR-UHFFFAOYSA-N
1-piperidin-4-yl-1,3-dihydro-benzoimidazol-2-one
1,3-dihydro-1-(4-piperidinyl)-2h-benzimidazol-2-one
1-(4-piperidyl)benzimidazolin-2-one
1-piperidin-4-yl-1,3-dihydro-2h-benzimidazol-2-one
4-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-piperidine
1-(4-piperidinyl)-2h-benzimidazol-2-one
4-(2-oxo-1-benzimidazolinyl)-piperidine
1,3-dihydro-1-(4-piperidinyl)benzoimidazol-2-one
1-piperidin-4-yl-1,3-dihydro-benzimidazol-2-one
1-piperidin-4-yl-1,3-dihydrobenzimidazol-2-one
4-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)piperidine
4-(2-keto-1-benzimidazolinyl)piperadine
4(2-keto-1-benzimidazolinyl)piperidine
4-(2-keto-1-benzimidazolyl)piperidine
4-(1,3-dihydro-2h-benzimidazol-2-on-1-yl)piperidine
SCHEMBL44492
NCGC00262912-01
tox21_113910
dtxsid0057679 ,
dtxcid1031468
cas-20662-53-7
J-200160
CHEMBL3331429
mfcd00005714
benperidol imp. a (ep); 1-(piperidin-4-yl)-1,3-dihydro-2h-benzimidazol-2-one; benperidol impurity a
AS-35672
Q27260404
1-(piperidin-4-yl)-1h-benzo[d]imidazol-2-ol
CS-0200083
3-(4-piperidyl)-1h-benzimidazol-2-one
1-(4-piperidyl)benzimidazol-2(3h)-one
SY081598
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Pimozide Pathway, Pharmacokinetics51

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency43.64860.01237.983543.2770AID1645841
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1188174Induction of apoptosis in human K562 cells by annexin V/propidium iodide staining-based flow cytometric analysis2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.
AID1188173Cytotoxicity against human K562 cells after 48 hrs by trypan blue dye exclusion test2014Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18
Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (40.00)24.3611
2020's6 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.71 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index54.30 (26.88)
Search Engine Supply Index2.84 (0.95)

This Compound (32.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pimozide
Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.		2.110benzimidazoles;
heteroarylpiperidine;
organofluorine compound		antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510